Consensus on Biological Agents in Treating Patients With Inflammatory Bowel Disease
10.3969/j.issn.1008-7125.2022.10.005
- Author:
Minhu CHEN
1
;
Kaichun WU
2
Author Information
1. Department of Gastroenterology, The First Affiliated Hospital, Sun Yat⁃sen University
2. National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Air Force Medical University
- Publication Type:Journal Article
- Keywords:
Biological Agents;
Expert Consensus;
Inflammatory Bowel Disease;
Therapy
- From:
Chinese Journal of Gastroenterology
2022;27(10):601-614
- CountryChina
- Language:Chinese
-
Abstract:
Biological agents have been increasingly used in the treatment of inflammatory bowel disease (IBD) in China. As the types of biologics and approved indications gradually increase, the rationale, effective and safe use of various biological agents pose new challenges to clinicians. In order to standardize the use of biological agents to treat IBD, Inflammatory Bowel Disease Quality Control Center and Inflammatory Bowel Disease Group of Chinese Society of Gastroenterology organized experts to formulate this guidance on indications, contraindications, effectiveness, screening and preventing opportunistic infections, methods of application, response monitoring, issues for special population and safety for use of biological agents. This consensus is expected to facilitate the standard use of biologics in patients with IBD in China.
